The effect of the steroid-sparing response to low-dose methotrexate on bone metabolism in glucocorticoid-dependent asthmatics

Clinica Chimica Acta

Volumn 341, Issue 1-2, 2004, Pages 157-163

  Girgis, Samia I ^a   Nwokeji, Amanda ^a   Shakur, B Haleema ^a   Ind, Philip W ^a   Shiner, Robert J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bone markers; Bone metabolism; Glucocorticoid dependent asthmatics; Methotrexate; Steroids

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; CORTICOSTEROID; DEOXYPYRIDINOLINE; GLUCOCORTICOID; METHOTREXATE; OSTEOCALCIN; PREDNISOLONE; STEROID; TELOPEPTIDE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; ASTHMA; BLOOD SAMPLING; BONE DENSITY; BONE LEVEL; BONE METABOLISM; BONE MINERAL; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MEASUREMENT; OSSIFICATION; OSTEOLYSIS; PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEQUENCE ANALYSIS; URINALYSIS;

EID: 1142285324     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.11.022     Document Type: Article

References (31)

1. Weinblatt M.E., Coblyn J.S., Fox D.A.et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312:1985;818-822.
2. Rees R.B., Bennett J.H., Maibach H.J. Methotrexate in psoriasis. Arch. Dermatol. 95:1967;2-11.
3. Feagan B.G., Rochon J., Fedorach R.N.et al. Methotrexate for the treatment of Crohn's disease. N. Engl. J. Med. 332:1995;292-297.
4. Shulimzon T.R., Shiner R.J. A risk-benefit assessment of methotrexate in corticosteroid-dependent asthma. Drug Saf. 4:1996;283-290.
5. Marin M.G. Low-dose methotrexate spares usage in steroid-dependent asthmatic patients: a meta-analysis. Chest. 112:1997;29-33.
6. Aaron S.D., Dales R.E., Pham B. Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomised clinical trials. Respir. Med. 92:1998;1059-1065.
7. Shiner R.J., Nunn A.J., Chung K.F., Geddes D.M. Randomised, double blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet. 336:1990;137-140.
8. Ragab A.H., Frech R.S., Vietti T.J. Osteoporotic fractures secondary to methotrexate therapy of acute leukaemia in remission. Cancer. 25:1970;580-585.
9. Schwartz A.M., Leonidas J.C. Methotrexate osteopathy. Skeletal Radiol. 11:1984;13-16.
10. Zonneveld I.M., Bakker W.K., Dijkstra P.F., Bos J.D., Van Soesbergen R.M., Dinant H.J. Methotrexate osteopathy in long-term, low dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch. Dermatol. 132:1996;184-187.
11. May K.P., West S.G., McDermott M.T., Huffer W.E. The effects of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum. 37:1994;201-206.
12. May K.P., Mercill D., McDermot M.T., West S.G. The effect of methotrexate on mouse bone cell in culture. Arthritis Rheum. 39:1996;489-494.
13. Suzuki Y., Nakagawa M., Masuda C., Ide M., Uehara R., Ichikawa Y., Mizushima Y. Short-term low dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvent induced arthritis. J. Rheumatol. 24:1997;1890-1895.
14. El-Miedany Y.M., Abubakr I.H., El-Baddini M. Effect of low dose methotrexate on markers of bone metabolism in patients with rheumatoid arthritis. J. Rheumatol. 25:1998;2083-2087.
15. Manolagas S.C., Weinstein R.S. New development in the pathogenesis and treatment of steroid-induced osteoporosis. J. Bone Miner. Res. 14:1999;1061-1066.
16. Patschan D., Loddenkemper K., Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone. 29:2001;498-505.
17. Reid D.M., Evans M.C., Wattie D.J., Ames R., Cundy T.F. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatics. Osteoporos. Int. 2:1992;103-105.
18. Rizzato G., Montemurro L. Reversibility of exogenous corticosteroid- induced none loss. Eur. Respir. J. 6:1993;116-119.
19. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102:1998;274-282.
20. Weinstein R.S., Nicholas R.W., Manolagas S.C. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J. Clin. Endocrinol. Metab. 85:2000;2907-2912.
21. Calvo M.S., Eyre D.R., Gundberg C.M. Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 17:1996;333-368.
22. Morrison N., Eisman J. Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promotor. J. Bone Miner. Res. 8:1993;969-975.
23. Morrison N.A., Shine J., Fragonas J.C., Verkest V., McMenemy L., Eisman J.A. 1,25-DihydroxyvitaminD-responsive element and glucocorticoid repression in the osteocalcin gene. Science. 246:1989;1158-1161.
24. Lukert B.P., Higgins J.C., Stoskopf M.M. Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J. Clin. Endocrinol. Metab. 62:1986;1056-1058.
25. Nielson H.K., Charles P., Mosekilde L. The effect of single oral doses of prednisolone on the circadian rhythm of serum osteocalcin in normal subjects. J. Clin. Endocrinol. Metab. 67:1988;1025-1030.
26. Puolijoki H., Liippo K., Herrala J., Salmi J., Tala E. Inhaled beclomethasone decreases osteocalcin in postmenopausal asthmatic women. Bone. 13:1992;285-288.
27. Meeran K., Hattersley A., Burrin J., Shiner R., Ibbertson K. Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am. J. Respir. Crit. Care Med. 151:1995;333-336.
28. Cosman F., Nieves J., Herbert J., Shen V., Lindsay R. High dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J. Bone Miner. Res. 9:1994;1097-1106.
29. Lukert B.P., Higgins J.C. Markers of bone remodelling in patients taking glucocorticoids. J. Bone Miner. Res. 10(Suppl. 1):1995;211.
30. Ebeling P.R., Erbas B., Hooper J.L., Wark J.D., Rubinfeld A.R. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J. Bone Miner. Res. 13:1998;1283-1289.
31. Cranney A.B., McKendry R.J., Wells G.A., Ooi D.S., Kanigsberg N.D., Kraag G.R.et al. The effect of low dose methotrexate on bone density. J. Rheumatol. 28(11):2001;2395-2399.